Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This study aims at investigating the therapeutic potential of recombinant human Nerve Growth
Factor ( rhNGF ) eye drops treatment in patients with Retinitis Pigmentosa (RP) associated
with cystoid macular edema (CME) in a phase II, randomized, double-masked, controlled
clinical trial.